Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease
Trial ID or NCT#
NCT02160145
Status
NOT RECRUITING
Purpose
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD).
Investigator(s)
Richard Lafayette, MD
Contact us to find out if this trial is right for you.
CONTACT
Kshama Mehta
(650) 736-1822
View on ClinicalTrials.gov
About this Clinical Trial
Your Message Will Go To
Kshama Mehta650-736-1822